NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Caris Life Sciences, Inc. (CAI) Stock Analysis

Caris Life Sciences, Inc. (CAI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CAI

$25.07

−$0.25 (−0.99%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CAI with… →

CAI Key Statistics

As of Sep 4, 2026
Trading
Open
$24.88
Previous Close
$25.32
Day's Range
24.47–25.14
52-Week Range
14.19–35.47
Volume
4.71M
Valuation
Market Cap
$7.09B
P/E Ratio
2.62
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
66.35
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.16
EPS (ttm)Profit attributable to each share over the last twelve months.
9.58
Financials (FY)
Revenue (FY)
$812.03M+96.97%
Net Income (FY)
−$68.09M
Profit marginThe share of revenue left as profit after all costs and taxes.
10.62%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
282.68M
1-Year Return
−31.03%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
4.28M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CAI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−7.08%
2025 (partial year)−3.64%

As of September 4, 2026.

CAI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$812.03M−$68.09M−8.4%
2024$412.26M−$281.89M−68.4%
2023$306.13M−$341.42M−111.5%
2022$258.49M−$320.83M−124.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$812.03M$539.17M$45.11M−$68.09M−8.4%
2024$412.26M$178.78M−$257.12M−$281.89M−68.4%
2023$306.13M$89.31M−$319.55M−$341.42M−111.5%
2022$258.49M$80.02M−$315.76M−$320.83M−124.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CAI Valuation vs Biotechnology Median

Median of 656 stocks
MetricCAIBiotechnology medianvs median
P/E2.6212.570.2x the median
P/S ratio7.1615.2653% below
Profit margin10.62%0.00%10.6 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Caris Life Sciences, Inc. (CAI) carries a market capitalisation of $7.09B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 1,846.

The 52-week range on file runs from $14.19 to $35.47. CAI last closed at $25.07 on September 4, 2026. That is −$0.25 (−0.99%) against the previous close. The latest close sits 76.67% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $812.03M. Against the prior fiscal year total of $412.26M, that is a change of +96.97%. The same year closed with a net loss of $68.09M. Profit margin runs at 10.62%. That is 10.6 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 9.58.

Across the 4 fiscal years on file, revenue moves from $258.49M in 2022 to $812.03M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

CAI trades at a trailing price-to-earnings ratio of 2.62. That is 0.2 times the Biotechnology median of 12.57. On forward earnings the ratio is 66.35. The price-to-sales ratio is 7.16. On price-to-sales that is 53.08% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −31.03%. Daily returns over the trailing 1 year annualize to a volatility of 65.56%.

Growth & Income

The record shows no dividend for CAI.

2026 is still running; the price is −7.08% year to date.

Peer Comparison

Caris Life Sciences, Inc. (CAI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Caris Life Sciences, Inc. CAI $7.09B 2.6
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Caris Life Sciences, Inc. trades at a P/E of 2.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Visit website →